Overview

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Aadi Bioscience, Inc.

Treatments:

Sirolimus